Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: A new system for anti-human immunodeficiency virus gene therapy

Journal of Virology

Volumn 70, Issue 11, 1996, Pages 8234-8240

  Cannon, Paula M ^a   Kim, Narry ^a   Kingsman, Susan M ^a   Kingsman, Alan J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSACTIVATOR PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; GENE THERAPY; GENETIC TRANSDUCTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; VIRUS INHIBITION;

EID: 0029795285     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.11.8234-8240.1996     Document Type: Article

References (56)

1. Adam, M. A., N. Ramesh, A. D. Miller, and W. A. Osborne. 1991. Internal initiation of translation in retroviral vectors carrying picornavirus 5′ non-translated regions. J. Virol. 65:4985-4990.
2. Adams, S. E., I. D. Johnson, M. Braddock, A. J. Kingsman, S. M. Kingsman, and R. M. Edwards. 1988. Synthesis of a gene for the HIV transactivator protein TAT by a novel single stranded approach involving gap repair in vivo. Nucleic Acids Res. 16:4287-4298.
3. Arya, S. K., C. Guo, S. F. Josephs, and F. Wong-Staal. 1982. Trans-activator gene of HTLV-III. Science 229:69-73.
4. Bahner, I., C. Zhou, X.-J. Yu, Q.-L. Hap, J. C. Guatelli, and D. B. Kohn. 1993. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J. Virol. 67:3199-3207.
5. Berkhout, B., and K.-T. Jeang. 1992. Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. J. Virol. 66:139-149.
6. Bevec, D., M. Dobrovnik, J. Hauber, and E. Bohnlein. 1992. Inhibition of human immunodeficiency type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc. Natl. Acad. Sci. USA 89:9870-9874.
7. Bowtell, D. D. L., S. Cory, G. R. Johnson, and T. J. Gonda. 1988. Comparison of expression in homeopathic cells by retroviral vectors carrying two genes. J. Virol. 62:2464-2473.
8. Braddock, M., A. M. Thorburn, A. Chambers, G. D. Elliot, G. J. Anderson, A. J. Kingsman, and S. M. Kingsman. 1990. A nuclear post-translational block imposed by the HIV-1 U3 region is relieved by the Tat-TAR interaction. Cell 62:1123-1133.
9. Brady, H., C. G. Miles, D. J. Pennington, and E. A. Dzierzak. 1994. Specific ablation of HIV Tat-expressing cells by conditionally toxic retroviruses. Procl. Natl. Acad. Sci. USA 91:365-369.
10. Bushman, F. D., and R. Craigie. 1990. Sequence requirements for integration of Moloney murine leukemia virus DNA in vitro. J. Virol. 64:5645-5648.
11. Cannon, P. M., W. Wilson, E. D. Byles, S. M. Kingsman and A. J. Kingsman. 1994. Human immunodeficiency virus type 1 integrase: effects on viral replication of mutations at highly conserved residues. J. Virol. 68:4768-4775.
12. Caruso, M., and D. Klatzman. 1992. Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected population. Proc. Natl. Acad. Sci. USA 89:182-186.
13. Correll, P. H., S. Colilla, and S. Karlsson. 1994. Retroviral vector design for long-term expression in murine hematopoletic cells in vivo. Blood 84:1812-1822.
14. Cullen, B. R., P. T. Lomedico, and G. Ju. 1984. Transcriptional interference in avian retroviruses - implications for the promoter insertion model of leukaemogenesis. Nature (London) 307:241-245.
15. Duch, M., K. Paludan, P. Jorgensen, and F. S. Pederson. 1994. Lack of correlation between basal expression levels and susceptibility to transcriptional shutdown among single-gene murine leukemia virus vector proviruses. J. Virol. 68:5596-5601.
16. Emerman, M., and H. M. Temin. 1984. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39:459-467.
17. Emerman, M., and H. M. Temin. 1986. Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol. Cell. Biol. 6:792-800.
18. Ensoli, B., L. Buonaguro, G. Barillari, V. Fiorelli, R. Gendelman, R. A. Morgan, P. Wingfield, and R. C. Gallo. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:277-287.
19. Fujita, M., K. Murata, and H. Shiku. 1994. Selective inhibition of human T-lymphotropic virus type I-transformed human T-cell growth by a tax-targeted conditionally cytotoxic recombinant retrovirus. Blood 84:2591-2596.
20. Ghattas, I. R., J. R. Sanes, and J. E. Majors. 1991. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirtis in cultured cells and in embryos. Mol. Cell. Biol. 11:5848-5829.
21. Hantzopoulos, P. A., B. A. Sullenger, G. Ungers, and E. Gilboa. 1989. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc. Natl. Acad. Sci. USA 86:3519-3523.
22. Harrison, G. S., C. J. Long, T. J. Curiel, F. Maxwell, and I. H. Maxwell. 1992 Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diptheria toxin A chain gene. Hum. Gene Ther. 3:461-469.
23. Hatzoglou, M. H., F. Bosch, E. Park, and R. W. Hanson. 1991. Hormonal control of interacting promoters introduced into cells by retroviruses. J. Biol. Chem. 266:8416-8425.
24. Hatzoglou, M. H., E. Park, A. Wynshaw-Boris, H. C. Kaung, and R. W. Hanson. 1988. Hormonal regulation of chimeric genes containing the phosphoenolpyruvate carboxykinase promoter regulatory region in hepatoma cells infected by murine retroviruses. J. Biol. Chem. 263:17798-17809.
25. Higuchi, R. 1990. Recombinant PCR, p. 177-183. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocots: a guide to methods and applications. Academic Press, San Diego.
26. Kadesch, T., and P. Berg. 1986. Effects of the position of the simian virus 40 enhancer on expression of multiple transcription units in a single plasmid. Mol. Cell. Biol. 6:2593-2601.
27. Karlsson, S., T. Papayannopoulou, S. G. Schweiger, G. Stamatoyannopoulos, and A. W. Nienhuis. 1987. Retroviral-mediated transfer of human globin genes leads to regulated production of RNA and protein. Proc. Natl. Acad. Sci. USA 84:2411-2415.
28. Katz, R. A., and A. M. Skalka. 1994. The retroviral enzymes. Annu. Rev, Biochem. 63:133-173.
29. Kim, S., R. Byrn, J. Groopeman, and D. Baltimore. 1989. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol. 63:3708-3713.
30. Lenz, J., D. Celander, R. L. Crowther, R. Patarca, D. W. Perkins, and W. Haseltine. 1984. Determination of the leukaemogenicity of a murine retrovirus by sequence within the long terminal repeat. Nature (London) 308: 467-480.
31. Li, M., P. A. Hantzopoulos, D. Banerjee, S. C. Zhao, B. I. Schweitzer, E. Gilboa, and J. R. Bertino. 1992. Comparison of expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. Hum. Gene Ther. 3:381-390.
32. Liem, S. E., A. Ramezani, X. Li, and S. Joshi. 1993. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum. Gene Ther. 4:625-634.
33. Lisziewicz, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz, and R. C. Gallo. 1993. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy for AIDS. Proc. Natl. Acad. Sci. USA 90:8000-8114.
34. Lisziewicz, J., D. Sun, B. Trapnell, M. Thomson, H.-K. Chang, B. Ensoli, and B. Peng. 1995. An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J. Virol. 69:206-212.
35. Liu, J., C. Woffendin, Z. Yang, and G. J. Nabel. 1994. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Gene Ther. 1:32-37.
36. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function. Cell 58:205-214.
37. Malim, M. H., W. W. Friemuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen, and G. J. Nabel. 1992. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176:1197-1201.
38. McLachlin, J. R., N. Mittereder, M. B. Daucher, M. Kadan, and M. A. Eglilis. 1993. Factors effecting retroviral vector function and structural integrity. Virology 195:1-5.
39. Morgan, R. A., L. Couture, O. Elroy-Stein, J. Ragheb, B. Moss, and W. F. Anderson. 1992. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 20:1293-1299.
40. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
41. Murphy, J. E., and S. P. Goff. 1989. Construction and analysis of deletion mutations in the US region of Moloney murine leukemia virus: effects on RNA packaging and reverse transcription. J. Virol. 63:319-327.
42. Newstein, M., E. J. Stanbridge, G. Casey, and P. R. Shank. 1990. Human chromosome 12 encodes a species-specific factor which increases human immunodeficiency virus type 1 tot-mediated trans-activation in rodent cells. J. Virol. 64:4565-4567.
43. Olsen, P., H. M. Temin, and R. Dornberg. 1992. Unusually high frequency of reconstitution of long terminal repeats in U3-minus retrovirus vectors by DNA recombination or gene conversion. J. Virol. 66:1336-1343.
44. Overall, R. W., K. E. Weisser, and D. Cosman. 1988. Stably transmitted triple-promoter retroviral vectors and their use in transformation of primary mammalian cells. Mol. Cell. Biol. 8:1803-1808.
45. Page, K. A., N. R. Landau, and D. R Littman. 1990. Construction and use of a human immunodeficiency, virus vector for analysis of virus infectivity. J. Virol. 64:5270-5276.
46. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
47. Riddell, S. R., M. Elliot, D. A. Lewinsohn, M. J. Gilbert, L. Wilson, S. A. Manley, S. D. Lupton, R. W. Overell, T. C. Reynolds, L. Corey, and P. D. Greenberg. 1996. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. 2:216-223.
48. Scharfman, R., J. H. Axelrod, and I. M. Verma. 1991 Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc. Natl. Acad. Sci. USA 88:4626-4630.
49. Soneoka, Y., P. M. Cannon, E. E. Ramsdale, J. S. Griffiths, G. Romano, S. M. Kingsman, and A. J. Kingsman. 1995. A transient three-plasmid expression system for the production of high liter retroviral vectors. Nucleic Acids Res. 23:628-633.
50. Stuhlman, H., R. Jaenisch, and R. C. Mulligan. 1989. Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance. Mol. Cell. Biol. 9:100-108.
51. Su, Y., W. Popik, and P. A. Pitha. 1995. Inhibition of human immunodeficiency virus type 1 replication by a Tat-activated, transduced interferon gene: targeted expression to human immunodeficiency virus type 1-infected cells. J. Virol. 69:110-121.
52. Vile, R., N. Miller, Y. Chernajovsky, and I. Hart. 1994. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve targeted expression of the HSV tk or IL-2 genes. Gene Ther. 1:307-316.
53. Xu, L., J.-K. Lee, J. A. Wolff, and T. Friedmann. 1989. Factors effecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 171:331-341.
54. Yee, J.-K., J. C. Moores, D. J. Jolly, J. A. Wolff, J. G. Respess, and T. Friedmann. 1987. Gene expression from transcriptionally disabled retroviral vectors. Proc. Natl. Acad. Sci. USA 84:5197-5201.
55. Yu, M., E. Poeschla, and F. Wong-Staal. 1994. Progress towards gene therapy for HIV infection. Gene Ther. 1:13-26.
56. Yu, S.-F., T. von Ruden, P. W. Kantoff, C. Garber, M. Seiberg, U. Ruther, W. F. Anderson, E. F. Wagner, and E. Gilboa. 1986. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 83:3194-3198.